Anika Therapeutics Q1 2026 Earnings Call Summary
Anika Therapeutics reported Q1 2026 earnings with commercial channel growth of 12% and OEM channel growth of 14%, driven by the Integrity platform and international OA pain management performance. The company also outlined its full-year 2026 revenue guidance and ongoing product development initiatives.
Tickers: $ANIK
Topics: Commercial Growth Earnings Call FDA Review Product Development Revenue Guidance